Cover Image
市場調查報告書

嗜鉻細胞瘤:開發中產品分析

Pheochromocytoma - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 200475
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
嗜鉻細胞瘤:開發中產品分析 Pheochromocytoma - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 92 Pages
簡介

嗜鉻細胞瘤是罕見的疾病,一般是非癌性(良性)腫瘤,在腎上腺的細胞內相當發達。症狀有高血壓,強烈頭痛,身體顫抖,呼吸急促,便秘等。危險因子有第二型多發性內分泌腫瘤症、逢希伯-林道症候群(VHL)、第一型神經性纖維瘤等。

本報告提供嗜鉻細胞瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

嗜鉻細胞瘤 - 概要

嗜鉻細胞瘤 - 治療藥的開發

  • 開發平台(管線)概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

嗜鉻細胞瘤 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

嗜鉻細胞瘤的治療藥開發企業

  • Advanced Accelerator Applications SA
  • Exelixis Inc
  • MediaPharma srl
  • OctreoPharm Sciences GmbH
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Valeant Pharmaceuticals International Inc

藥物簡介

嗜鉻細胞瘤 - 暫停中的計劃

嗜鉻細胞瘤 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9828IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2017, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Pheochromocytoma - Overview
  • Pheochromocytoma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Pheochromocytoma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pheochromocytoma - Companies Involved in Therapeutics Development
  • Advanced Accelerator Applications SA
  • Exelixis Inc
  • Ipsen SA
  • Lixte Biotechnology Holdings Inc
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Valeant Pharmaceuticals International Inc
  • Pheochromocytoma - Drug Profiles
  • 177Lu-Satoreotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cabozantinib s-malate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • iobenguane sulfate I 131 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LB-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LMP-400 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lutetium Lu 177 dotatate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • metyrosine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONC-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PEN-221 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S-43126 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sunitinib malate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pheochromocytoma - Dormant Projects
  • Pheochromocytoma - Product Development Milestones
  • Featured News & Press Releases
  • Oct 04, 2017: Data from Pivotal Phase 2b Study of Progenics' AZEDRA (iobenguane I 131) to be Presented at the North American Neuroendocrine Tumor Society 2017 Annual Symposium
  • Aug 31, 2017: Progenics Pharmaceuticals Presents Data from AZEDRA Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma
  • Aug 31, 2017: Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA
  • Mar 30, 2017: Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA
  • Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA
  • Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra
  • Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015
  • Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma
  • Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015
  • Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma
  • Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma
  • Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications
  • Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pheochromocytoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, H2 2017
  • Pheochromocytoma - Pipeline by Exelixis Inc, H2 2017
  • Pheochromocytoma - Pipeline by Ipsen SA, H2 2017
  • Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
  • Pheochromocytoma - Pipeline by Pfizer Inc, H2 2017
  • Pheochromocytoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017
  • Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, H2 2017
  • Pheochromocytoma - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017
  • Pheochromocytoma - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Pheochromocytoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top